Glyxambi ® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union

Glyxambi ® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union

https://www.boehringer-ingelheim.com/press-release/T2D-Glyxambi-EU-approval-reco...

Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

More News: Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Jardiance | Research